Smith & Wesson (SWBI) 2026 10-K Analysis: MD&A Filing Changes

Smith & Wesson (SWBI) 2026 10-K analysis comparing MD&A changes, sales growth, tariff pressure, debt reduction, and capital allocation versus 2025.

Smith & Wesson SWBI 2026 10-K analysis showing MD&A filing changes

Smith & Wesson Brands (SWBI) was the only company meeting our filing-comparison criteria among 10-K annual reports filed with the SEC on 17 June 2026. This Smith & Wesson 10-K analysis compares the company’s 2026 filing with its 2025 annual report, highlighting stronger sales, higher earnings, debt reduction, continued dividend payments, and tariff pressure in MD&A.

Smith & Wesson 2026 10-K Filing Summary

  • SMITH & WESSON BRANDS, INC. (Low) — Smith & Wesson delivered better top-line growth and earnings in fiscal 2026, but tariffs remain a clear margin headwind.
RankCompanyCIKFull Filing SimilarityBusiness SimilarityRisk Factors SimilarityMD&A SimilarityMost Changed SectionAssessment
1SMITH & WESSON BRANDS, INC.10927960.9980.9990.9990.906MD&Alow
Rank1
Lowest similarity sectionMD&A
Assessmentlow
SEC filings2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text)

Smith & Wesson’s MD&A shows a better year in fiscal 2026, with higher sales, improved gross profit, and stronger earnings per share. The company also reduced revolver debt while continuing to return cash to shareholders through dividends. The main offset is that tariffs pressured margins, so profitability still depends on cost control and product mix.

Key Changes From the 2025 10-K

  • MD&A now says fiscal 2026 net sales were $523.8 million, up $49.2 million, or 10.4%, from the prior year.
  • Gross profit rose $13.9 million, with gross margin up 10 basis points, helped by lower promotional costs and lower federal firearms excise taxes, partly offset by unfavorable fixed-cost absorption and a 100-basis-point tariff hit.
  • Net income increased to $18.5 million, or $0.41 per diluted share, from $13.4 million, or $0.30 per diluted share.
  • The company added that it repaid $60.0 million on its revolving credit facility and paid $23.2 million in dividends during fiscal 2026.

Revenue, Margins, and Tariff Pressure

Fiscal 2026 net sales of $523.8 million topped the prior year by 10.4%, and gross margin still expanded by 10 basis points even after absorbing a 100-basis-point tariff hit — lower promotional spending and lower federal firearms excise taxes offset the tariff drag and unfavorable fixed-cost absorption. Higher sales and profit suggest demand improved, but the size of the tariff offset shows margin gains are still fragile and depend on continued cost discipline.

Debt Reduction and Capital Allocation

Smith & Wesson repaid $60.0 million on its revolving credit facility in fiscal 2026 while continuing to pay dividends — $23.2 million, versus $23.1 million the year before. Paying down debt while holding the dividend steady is a positive liquidity signal, and management’s continued emphasis on new products and market leadership points to a growth strategy that still depends on firearm demand staying strong.

Most Changed Section: MD&A

MD&A was the company’s most-changed section in this filing — Business and Risk Factors similarity each came in at 0.999, while MD&A similarity was just 0.906, the widest gap of any section. The rewritten MD&A excerpts below show exactly where management’s year-over-year narrative changed.

2025 filing excerpt – MD&A

See also the discussion below related to an immaterial correction of an error. 2025 Highlights Our operating results for fiscal 2025 included the following: • Net sales of $474.7 million represented a decrease of $61.2 million, or 11.4%, from the prior fiscal year. • Gross profit decreased $30.9 million, or 19.6%, from the prior fiscal year, primarily as a result of lower sales volume and a shift in product mix. Gross margin decreased 270 basis points from the prior fiscal year in spite of a $3.2 million legal settlement recognized in the prior year comparable period.

2026 filing excerpt – MD&A

This section generally discusses year-to-year comparisons between fiscal 2026 and fiscal 2025. 2026 Highlights Our operating results for fiscal 2026 included the following: • Net sales of $523.8 million represented an increase of $49.2 million, or 10.4%, over the prior fiscal year. • Gross profit increased $13.9 million, or 10.9%, over the prior fiscal year, primarily because of higher sales volume. Gross margin increased by ten basis points from the prior fiscal year primarily due to lower promotional costs and lower federal firearms excise taxes, partially offset by unfavorable fixed-cost absorption and a 100-basis point impact from higher tariffs. • Net income was $18.5 million, or $0.41 per diluted share, compared with net income of $13.4 million, or $0.30 per diluted share, for the prior fiscal year. • During fiscal 2026, we paid $23.2 million in dividends compared with $23.1 million in fiscal 2025. • During fiscal 2026, we repaid $60.0 million on our revolving credit facility.

2025 filing excerpt – MD&A

Gross margin decreased 270 basis points from the prior fiscal year in spite of a $3.2 million legal settlement recognized in the prior year comparable period. Excluding the impact of the prior year legal settlement, gross margin was 330 basis points lower as a result of higher material costs, higher promotional costs, and a shift in product mix to lower margin products, partially offset by lower inventory adjustments (including standard cost revaluations, shrink, and excess inventory write downs). • Net income was $13.4 million, or $0.30 per diluted share, compared with net income of $41.4 million, or $0.89 per diluted share, for the prior fiscal year. • During fiscal 2025, we paid $23.1 million in dividends compared with $22.0 million in fiscal 2024. • During fiscal 2025, we purchased 1,844,073 shares of our common stock for $25.5 million. Immaterial Correction…

2026 filing excerpt – MD&A

2026 Highlights Our operating results for fiscal 2026 included the following: • Net sales of $523.8 million represented an increase of $49.2 million, or 10.4%, over the prior fiscal year. • Gross profit increased $13.9 million, or 10.9%, over the prior fiscal year, primarily because of higher sales volume. Gross margin increased by ten basis points from the prior fiscal year primarily due to lower promotional costs and lower federal firearms excise taxes, partially offset by unfavorable fixed-cost absorption and a 100-basis point impact from higher tariffs. • Net income was $18.5 million, or $0.41 per diluted share, compared with net income of $13.4 million, or $0.30 per diluted share, for the prior fiscal year. • During fiscal 2026, we paid $23.2 million in dividends compared with $23.1 million in fiscal 2025. • During fiscal 2026, we repaid $60.0 million on our revolving credit facility. Key Performance Indicators We evaluate the performance of our business based upon operating profit and net income, which includes net sales, cost of sales, selling and administrative expenses, and certain components of other income and expense.

Why SEC Filing Changes Matter

Research by Cohen et al. (Lazy Prices, 2020) — using the complete history of SEC filings from 1995 to 2014 — shows that when firms make active changes to their annual disclosures, those changes convey an important signal about future operations and returns. A portfolio that shorted "changers" and bought "non-changers" earned over 22% per year in annual alpha historically. Changes to the Risk Factors section, Business description, and language referring to the executive team were especially informative. Critically, these returns accrued gradually as information was later revealed through news and earnings — not at the time of filing — suggesting many investors remain inattentive to these simple, public signals. This snapshot is a starting point for deeper investigation, not a buy or sell recommendation.

SEC What Changed Methodology

Three 10-K annual reports were filed with the SEC on 17 June 2026; Smith & Wesson Brands was the only one meeting our filing-comparison criteria. To qualify, a company must have filed an annual 10-K report on the target date and have a prior-year 10-K available for a direct year-over-year comparison — a prior-year filing was not available for VITASPRING BIOMEDICAL CO. LTD. (1697884) or Somitos Corp. (2074643), so they were excluded from the ranking.

Each company is scored on how similar its current annual filing text is to the prior year. Scores run from 0 to 1 — a score of 1 means the language is essentially unchanged; a lower score means more has changed. We flag three sections that carry the most disclosure signal: Business, Risk Factors, and MD&A. Academic research suggests that lower-scoring companies warrant closer attention from investors — those that make significant changes to their filings have historically underperformed, while stable-language filers have earned positive abnormal returns.

For more like this, see the full SEC What Changed archive, browse more equity research reports, or subscribe to Quantitative Research Notes for new filing-change alerts as soon as they publish.

Research disclaimer

This material is provided for research and educational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any security or strategy.

Receive research notes

Get concise market research, backtests, and risk notes when new work is published.





Double opt-in. No personalized investment advice.

Leave a Reply

Your email address will not be published. Required fields are marked *